ES2659353T3 - Métodos y formulaciones nutricionales para aumentar la eficacia y reducir los efectos secundarios del tratamiento del cáncer - Google Patents

Métodos y formulaciones nutricionales para aumentar la eficacia y reducir los efectos secundarios del tratamiento del cáncer Download PDF

Info

Publication number
ES2659353T3
ES2659353T3 ES10825771.8T ES10825771T ES2659353T3 ES 2659353 T3 ES2659353 T3 ES 2659353T3 ES 10825771 T ES10825771 T ES 10825771T ES 2659353 T3 ES2659353 T3 ES 2659353T3
Authority
ES
Spain
Prior art keywords
food
component
meals
providing
cancer patient
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
ES10825771.8T
Other languages
English (en)
Inventor
Valter D. Longo
Changhan Lee
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University of Southern California USC
Original Assignee
University of Southern California USC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by University of Southern California USC filed Critical University of Southern California USC
Application granted granted Critical
Publication of ES2659353T3 publication Critical patent/ES2659353T3/es
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • G—PHYSICS
    • G06—COMPUTING; CALCULATING OR COUNTING
    • G06Q—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR ADMINISTRATIVE, COMMERCIAL, FINANCIAL, MANAGERIAL OR SUPERVISORY PURPOSES; SYSTEMS OR METHODS SPECIALLY ADAPTED FOR ADMINISTRATIVE, COMMERCIAL, FINANCIAL, MANAGERIAL OR SUPERVISORY PURPOSES, NOT OTHERWISE PROVIDED FOR
    • G06Q10/00—Administration; Management
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
    • A23L13/00—Meat products; Meat meal; Preparation or treatment thereof
    • A23L13/60—Comminuted or emulsified meat products, e.g. sausages; Reformed meat from comminuted meat product
    • A23L13/65—Sausages
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23P—SHAPING OR WORKING OF FOODSTUFFS, NOT FULLY COVERED BY A SINGLE OTHER SUBCLASS
    • A23P20/00—Coating of foodstuffs; Coatings therefor; Making laminated, multi-layered, stuffed or hollow foodstuffs
    • A23P20/20—Making of laminated, multi-layered, stuffed or hollow foodstuffs, e.g. by wrapping in preformed edible dough sheets or in edible food containers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
    • A61K31/07—Retinol compounds, e.g. vitamin A
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
    • A61K31/202—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids having three or more double bonds, e.g. linolenic
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/365—Lactones
    • A61K31/375—Ascorbic acid, i.e. vitamin C; Salts thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/59—Compounds containing 9, 10- seco- cyclopenta[a]hydrophenanthrene ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/02—Nutrients, e.g. vitamins, minerals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Business, Economics & Management (AREA)
  • Food Science & Technology (AREA)
  • Polymers & Plastics (AREA)
  • Nutrition Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Tourism & Hospitality (AREA)
  • Physics & Mathematics (AREA)
  • Theoretical Computer Science (AREA)
  • General Physics & Mathematics (AREA)
  • Economics (AREA)
  • Entrepreneurship & Innovation (AREA)
  • Human Resources & Organizations (AREA)
  • Marketing (AREA)
  • Operations Research (AREA)
  • Quality & Reliability (AREA)
  • Strategic Management (AREA)
  • General Business, Economics & Management (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Obesity (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Coloring Foods And Improving Nutritive Qualities (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)

Abstract

Un envase de comida terapéutica para su uso para proporcionar comidas a un paciente con cáncer, que retrasa el crecimiento del cáncer y mejora la eficacia de los fármacos quimioterapéuticos, comprendiendo el envase de comida terapéutica: un primer componente de comida dividido en comidas, que proporciona al paciente con cáncer como máximo el 50% de la ingesta calórica normal del paciente, proporcionando el primer componente de comida, al paciente con cáncer, de 700 a 1200 kcal/día, procediendo de la grasa al menos el 50% de las kilocalorías, proporcionando el primer componente de comida, comidas durante un primer período de tiempo predeterminado de aproximadamente 1 a 5 días; un segundo componente de comida dividido en comidas, proporcionando el primer componente de comida al paciente con cáncer, como máximo 500 kcal/día, proporcionando el segundo componente de comida, comidas durante un segundo período de tiempo predeterminado de aproximadamente 2 a 7 días; y una composición reponedora que comprende aminoácidos esenciales y otros aminoácidos no esenciales, ácidos grasos esenciales, minerales, vitaminas y/o extractos de verduras, durante un tercer período de tiempo predeterminado.
ES10825771.8T 2009-10-22 2010-10-22 Métodos y formulaciones nutricionales para aumentar la eficacia y reducir los efectos secundarios del tratamiento del cáncer Active ES2659353T3 (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US25415409P 2009-10-22 2009-10-22
US254154P 2009-10-22
PCT/US2010/053821 WO2011050302A2 (en) 2009-10-22 2010-10-22 Methods and nutritional formulations to increase the efficacy and reduce the side effects of cancer treatment

Publications (1)

Publication Number Publication Date
ES2659353T3 true ES2659353T3 (es) 2018-03-14

Family

ID=43900993

Family Applications (1)

Application Number Title Priority Date Filing Date
ES10825771.8T Active ES2659353T3 (es) 2009-10-22 2010-10-22 Métodos y formulaciones nutricionales para aumentar la eficacia y reducir los efectos secundarios del tratamiento del cáncer

Country Status (13)

Country Link
US (2) US20110118528A1 (es)
EP (1) EP2490684B1 (es)
JP (1) JP2013508411A (es)
CN (1) CN102753162A (es)
AU (2) AU2010310515B2 (es)
BR (1) BR112012009423A2 (es)
CA (1) CA2779282C (es)
DK (1) DK2490684T3 (es)
ES (1) ES2659353T3 (es)
PL (1) PL2490684T3 (es)
PT (1) PT2490684T (es)
RU (1) RU2549954C2 (es)
WO (1) WO2011050302A2 (es)

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2822178T3 (es) * 2012-10-22 2021-04-29 Univ Southern California Formulaciones dietéticas que promueven la regeneración de tejidos/órganos
US9237761B2 (en) * 2013-02-12 2016-01-19 University Of Southern California Methods and diets for lowering glucose and/or IGF-1 levels
US9386790B2 (en) * 2013-07-01 2016-07-12 University Of Southern California Fasting condition as dietary treatment of diabetes
US10172839B2 (en) 2014-03-06 2019-01-08 University Of Southern California Use of short term starvation regimen in combination with kinase inhibitors to enhance traditional chemo-drug efficacy and feasibility and reverse side effects of kinases in normal cells and tissues
ES2846153T3 (es) * 2014-03-06 2021-07-28 Univ Southern California Uso de régimen de inanición a corto plazo en combinación con inhibidores de cinasa para potenciar la eficacia y viabilidad de fármacos quimioterápicos tradicionales y revertir efectos secundarios de cinasas en células y tejidos normales
JP2017509671A (ja) * 2014-03-28 2017-04-06 ウニベルシタ デリィ ストゥディ ディ ジェノバ カロリー摂取量減少と協同したがん治療方法で使用されるチロシンキナーゼ阻害剤
EP3125904A4 (en) * 2014-04-02 2017-08-30 University of Southern California Autoimmunity and multiple sclerosis treatment
CA2982875C (en) 2015-04-16 2021-10-19 University Of Southern California Fasting mimicking diet (fmd) and glucose lowering drugs protect normal cells and generate cancer sensitizing conditions in response to standard and high glucose conditions induced by rapamycin and dexamethasone
CA2984891A1 (en) 2015-05-06 2016-11-10 University Of Southern California Fasting mimicking and enhancing diet for treating hypertension and lipid disorders
WO2017050849A1 (en) * 2015-09-21 2017-03-30 Ifom Fondazione Istituto Firc Di Oncologia Molecolare New therapeutic strategies against blood cancer
US20190029301A1 (en) * 2016-01-12 2019-01-31 University Of Southern California Use of long-term fasting mimicking as dietary treatment for multiple myeloma and other cancers
US10660932B2 (en) 2016-02-15 2020-05-26 University Of Southern California Drug combinations and methods to stimulate embryonic-like regeneration to treat diabetes and other diseases
EP4218751A3 (en) * 2016-02-23 2024-03-06 Cancer Research Technology Ltd Dietary product devoid of at least two non essential amino acid
ES2871060T3 (es) 2016-05-11 2021-10-28 Univ Southern California Dieta que imita el ayuno (FMD) como tratamiento inmunorregulador para enfermedades digestivas autoinmunitarias/inflamatorias
IT201700008499A1 (it) * 2017-01-26 2018-07-26 Univ Degli Studi Genova Composizione dietetica per la prevenzione e/o il trattamento dell’iperplasia dell’endometrio
US11284640B2 (en) 2017-02-14 2022-03-29 University Of Southern California Fasting mimicking diet
CN107951892A (zh) * 2018-01-19 2018-04-24 丽水学院 锌原卟啉在制备增强人结直肠癌细胞对5-氟尿嘧啶化疗敏感性药物中的应用
AU2019236242A1 (en) 2018-03-15 2020-10-01 University Of Southern California Fasting-mimicking diet (FMD) but not water-only fasting promotes reversal of inflammation and IBD pathology
DE212018000421U1 (de) * 2018-07-18 2021-03-01 Andreas Michalsen Auswirkungen einer kurzzeitigen Diät, die Fasten imitiert, auf die Lebensqualität und die Verträglichkeit einer Chemotherapie bei Patientinnen mit Krebs
CA3119100C (en) 2018-11-09 2024-06-04 Valter D. Longo Nutrition bar for intermittent fasting-mimicking
JP6747702B1 (ja) * 2019-05-10 2020-08-26 株式会社医療情報技術研究所 栄養処方管理システム
EP3968785A4 (en) 2019-05-14 2023-01-11 Tyme, Inc. COMPOSITIONS AND METHODS FOR TREATMENT OF CANCER
JP7376718B2 (ja) * 2019-12-13 2023-11-08 株式会社ベリタスバイオセラピューティクス 癌の予防または治療用薬学組成物
IT202000007153A1 (it) 2020-04-03 2021-10-03 Ifom Fondazione St Firc Di Oncologia Molecolare Apporto calorico ridotto e immunoterapia per il trattamento del cancro
US10905698B1 (en) 2020-05-14 2021-02-02 Tyme, Inc. Methods of treating SARS-COV-2 infections
CA3205396A1 (en) * 2020-12-17 2022-06-23 Licia Rivoltini Diet preparation for the nutrition of cancer patients with a restricted calorie intake
EP4066823A1 (en) 2021-03-30 2022-10-05 IFOM Fondazione Istituto Firc di Oncologia Molecolare Reduced caloric intake and anticancer agents for the treatment of cancer

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2074731C1 (ru) * 1994-12-29 1997-03-10 Игорь Александрович Бойко Фитокомплекс, обладающий противоопухолевым действием, и способ лечения онкологических больных
JP4740426B2 (ja) * 1997-03-17 2011-08-03 ビーティージー・インターナショナル・リミテッド 治療用組成物
WO2001006983A2 (en) * 1999-07-22 2001-02-01 Incell Corporation, Llc Fatty acids to minimize cancer therapy side effects
WO2005117542A2 (en) * 2004-05-10 2005-12-15 Novacea, Inc. Treatment of pancreatic cancer with active vitamin d compounds in combination with other treatments
WO2006043966A2 (en) * 2004-10-15 2006-04-27 University Of Tennessee Research Foundation Methods for inducing apoptosis in adipocytes
US20070116802A1 (en) * 2005-11-23 2007-05-24 Carl Germano High quality caloric composition
US20080038367A1 (en) * 2006-08-11 2008-02-14 Sal Saloum Nutritional supplement compositions and methods of preparing
RU2354369C2 (ru) * 2007-03-16 2009-05-10 Михаил Владимирович Кутушов Применение родамина 6ж в качестве лекарственного средства для лечения злокачественных новообразований и амилоидозов
US8211700B2 (en) * 2007-03-28 2012-07-03 University Of Southern California Induction of differential stress resistance and uses thereof
WO2009070378A1 (en) * 2007-11-26 2009-06-04 Nestec S.A. Compositions and methods for inhibiting the activation of dsrna-dependent protein kinase and tumor growth inhibition

Also Published As

Publication number Publication date
BR112012009423A2 (pt) 2017-06-13
EP2490684A2 (en) 2012-08-29
US20110118528A1 (en) 2011-05-19
DK2490684T3 (en) 2018-04-09
WO2011050302A3 (en) 2011-08-25
PT2490684T (pt) 2018-04-02
CN102753162A (zh) 2012-10-24
AU2016201607B2 (en) 2017-11-30
WO2011050302A2 (en) 2011-04-28
AU2010310515B2 (en) 2016-01-07
CA2779282A1 (en) 2011-04-28
US20210209516A1 (en) 2021-07-08
EP2490684B1 (en) 2018-01-03
AU2010310515A1 (en) 2012-05-17
CA2779282C (en) 2017-12-05
PL2490684T3 (pl) 2018-07-31
AU2016201607A1 (en) 2016-03-31
RU2012118588A (ru) 2013-11-27
JP2013508411A (ja) 2013-03-07
RU2549954C2 (ru) 2015-05-10
EP2490684A4 (en) 2016-05-04

Similar Documents

Publication Publication Date Title
ES2659353T3 (es) Métodos y formulaciones nutricionales para aumentar la eficacia y reducir los efectos secundarios del tratamiento del cáncer
Farahat et al. Effect of dietary supplementation of grape seed extract on the growth performance, lipid profile, antioxidant status and immune response of broiler chickens
ES2807781T3 (es) Composición de dieta para usar en un método terapéutico para reducir los niveles de glucosa en sangre y/o de IGF-1
ES2954473T3 (es) Aditivo para alimentación de ganado
ES2571856T3 (es) Uso de composiciones nutricionales para prevenir la adiposidad visceral
CO6351747A2 (es) Composicion nutricional para promover desarrollo y crecimiento saludables
RU2006130739A (ru) Питательная композиция для улучшения состояния кожи и предотвращения кожных заболеваний
BR112012033422A2 (pt) composições nutricionais de proteína alta, hipocalórica e métodos de usar as mesmas
BR112017009678A2 (pt) composição optimizada de nutrientes de ácidos graxos e método de preparação da mesma
EA201270274A1 (ru) Натуральный экстракт из цельных плодов банана (musa spp.)
Kale et al. Role of antioxidants and nutrition in oxidative stress: A review
JP2015510888A5 (es)
MX2009001156A (es) Composiciones de vitamina d y metodo de administracion a un ser humano.
ES2947500T3 (es) Composiciones orales antiparasitarias
Lim et al. Nutrients and dietary supplements for osteoarthritis
Owens Nutritional support to counteract muscle atrophy
HK1118722A1 (en) Use of a combination comprising l-carnitine or alkanoyl l-carnitine, lipid solubl benzoquinone and omega-3-polyunsaturated fatty acid for the preparation of a dietary supplement or medicament for the treatment of corneal diseases
Alagbe et al. Albizia lebbeck stem bark aqueous extract as alternative to antibiotic feed additives in broiler chicks diets: Haematology, Serum indices and oxidative status
Sahin et al. Role of the antioxidant defence system and transcription factors in preventing heat stress in poultry: a dietary approach
ES2716278T3 (es) Productos para administración oral que comprenden extractos de granada Punica granatum, pensados para un animal de compañía, y aplicaciones de los mismos
Sutili et al. Clove Oil, eugenol effective anesthetics for silver catfish, other Brazilian species
EA202092105A1 (ru) Фармацевтический состав или состав пищевой добавки на основе альфа-лактальбумина
US10499664B2 (en) Fish feed formulation of Hypericum perforatum, Rosamarinus officianalis or a mixture thereof
Alalwan Nutraceuticals and their role in promoting musculoskeletal healthy aging.
WO2019040459A3 (en) Composition and nutritional supplement made therefrom